Recently, you must have noticed. Many actors, directors, comedians, and influencers who were slightly on the obese side are suddenly showing up super lean. And not just a small 2-3 kg drop. We’re talking about massive 15-20 kg weight loss, sharp jawlines — all within months 👀

If you ask them, they’ll just say it's their workout & diet finally working. But the buzz is everywhere that they’re on GLP-1 drugs. In fact, Hansal Mehta (Director, Scam 1992) openly admitted to using it. Others may not say it, but the rumours are too loud to ignore.

So, what exactly are these GLP-1 drugs? It’s a class of medication that was originally made for people with Type 2 diabetes, as it helps the body release insulin & control blood sugar. Plus, it also mimics a hormone in your gut that tells your brain “you’re full, stop eating.”

It slows down digestion, keeps you full for longer, and naturally cuts down how much you eat — making you lose serious weight.

Now obviously, the moment Indians got to know about this magic jab, curiosity exploded. Because let’s be real, we love to mimic Bollywood – be it hair style, fashion, or even baby names. So when celebs started showing up thin overnight, people wanted the same shortcut.

And this time it was fair. Because it was personal. India is literally sitting on a diabetes & obesity time bomb. We already have 100M+ diabetics, the 2nd highest in the world & obesity is rising like crazy. Almost every family has someone struggling with sugar, weight, or BP.

So when people heard about an injection that not only helps you shed 15-20% of body weight, but also controls sugar and heart risks, it became a no-brainer. And, as expected, the global pharma giants jumped in quick.

Novo Nordisk brought in Ozempic and Wegovy. Eli Lilly launched Mounjaro. Each shot costs around ₹3,500-6,500 a week (₹15,000-25,000 a month). And still, even in a market like India where people bargain over vegetables, sales went crazy.

Mounjaro racked up ₹50 crore in sales within its first 90 days (March to June 2025). Wegovy managed ₹2.5 crore in its very first week in June 2025.

And honestly, this is just the beginning. Analysts are saying the anti-obesity drug market in India could grow 10x by 2030, touching ₹8,000-10,000 crore!!! That’s why global pharma didn’t waste time and rushed to launch here.

But wait. If the market is this big, why don’t our own Indian companies make these jabs at home? Wouldn’t it be way cheaper since India is literally the land of generics? The reason is simple: PATENTS. Till 2026, companies like Novo Nordisk and Eli Lilly hold the rights.

And these patents don’t just cover the drug itself. They also cover the formula of the main ingredients (like semaglutide & tirzepatide), the way the drug is manufactured, dosage levels, & even the injection design. So local pharma can’t sell the same drugs in India just yet.

Moreover, they defend these patents fiercely. Novo Nordisk dragged Dr. Reddy’s and OneSource to Delhi High Court in May 2025, after they imported semaglutide’s raw ingredient (API) and even started making finished versions of the drug.

The court sided with Novo in India and barred Dr. Reddy’s from selling semaglutide here until the patent expires in 2026. But it also allowed them to keep manufacturing and export to countries where the patent has already expired.

Also, let’s not forget that global giants have a 10-15 year head start. They poured billions into R&D, ran massive global trials, and filed patents across 100+ countries. By the time Indian pharma could react, the patent wall was already up.

But here’s where the story really flips. 2026 is almost here and the patents will start expiring in India soon. Once that protection lapses, anyone can legally manufacture and sell the same molecule here. And that’s the big break Indian pharma has been waiting for.

In fact, Dr. Reddy’s is already preparing semaglutide generics for 87 countries and Biocon launched a liraglutide generic in the UK. So the minute the patent wall falls, Indian pharma will be standing at the gate, ready to flood the Indian market with cheaper versions.

And that’s where things really change. A shot that costs ~₹25K/month today, could come down to ₹3K-4K or less within a few years. Making it accessible not just for the rich & upper middle class but also cab drivers, homemakers, etc. who are struggling with diabetes & obesity.

Meanwhile, even the Indian government is giving this a push. From 2026, pharma companies making GLP-1s will get incentives under the PLI scheme. So, the message is pretty clear: India doesn’t just want to make these shots for its own people.

It wants to be the world’s pharmacy for fat-loss jabs, the same way we once became for HIV medicines and vaccines. Of course, there are risks. In the US, Novo & Lilly already face lawsuits. Patients say they weren’t warned about side effects like nausea & stomach paralysis.

And this isn’t like popping a paracetamol. Most people need to stay on GLP-1s for months to maintain the weight loss. Hollywood already had its share of drama. Celebs like Sharon Osbourne and John Goodman lost weight so fast that their faces turned gaunt.

Cheeks sank, skin sagged, and people started calling it the Ozempic face. Even plastic surgeons say it’s due to rapid fat loss, which hollows the eyes and ages the face. So yes, some new studies even suggest semaglutide has its own benefits.

But the truth is, no one really knows what side effects might appear after years of use. So if India wants to win global trust, it can’t just flood the market with cheap versions. We must prove safety in clinical trials, track long-term effects & teach patients responsible use.

If you liked this read, do RePost🔄 the 1st post  and follow us @FinFloww for such reads every Monday, Wednesday and Friday!

Get our WhatsApp newsletter: https://whatsapp.com/channel/0...

@FinFloww @threadreaderapp unroll